Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
Abstract The objective of this study was to examine the maintenance of effect and safety after a hospital‐wide switch for economic reasons from adalimumab originator Humira® to biosimilar Amgevita® in real‐world rheumatoid arthritis (RA) patients and patient satisfaction with the switch. We conducte...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.1025 |